drugset / Trial / NCT01482195
Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)
Phase 1
Completed
6 enrolled
King Khaled Eye Specialist Hospital
King Faisal Specialist Hospital & Research Center · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study was to assess the safety of gene transfer via subretinal administration of rAAV2-VMD2-hMERTK in subjects with MERTK-associated retinitis pigmentosa (RP).
Timeline
- Start
- 2011-08
- Primary completion
- 2013-08
- Completion
- 2019-08
Publications
- Wang CY, Chen L, Lin TY, Huang SP. Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis. J Ophthalmol. 2025 Jun 12;2025:7014745. doi: 10.1155/joph/7014745. eCollection 2025.
- Parinot C, Nandrot EF. A Comprehensive Review of Mutations in the MERTK Proto-Oncogene. Adv Exp Med Biol. 2016;854:259-65. doi: 10.1007/978-3-319-17121-0_35.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rAAV2-VMD2-hMERTK | Gene therapy (AAV / viral vector) | — | Other |